Leveraging single-cell sequencing analysis and bulk-RNA sequencing analysis to forecast necroptosis in cutaneous

Jiaheng Xie1, Pengpeng Zhang2, Qikai Tang3

  • 1Department of Plastic Surgery, Xiangya Hospital, Central South University, Changsha, China.

PubMed

Insights

This study reveals significant heterogeneity in necroptosis, a cell death pathway, within cutaneous melanoma. A novel necroptosis-related signature (NRS) effectively predicts patient prognosis and highlights TSPAN10 as a key therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Cutaneous melanoma poses a significant challenge due to its aggressive nature and increasing incidence.
  • Variability in patient treatment response necessitates research into novel therapeutic targets, including programmed cell death pathways like necroptosis.

Purpose of the Study:

  • To investigate the heterogeneity of necroptosis in cutaneous melanoma using single-cell sequencing.
  • To develop and validate a necroptosis-related signature (NRS) for prognostic assessment.
  • To analyze the tumor microenvironment (TME) and identify key targets like TSPAN10.

Main Methods:

  • Utilized single-cell sequencing to analyze melanoma datasets (GEO and TCGA).
  • Employed 101 machine learning algorithms to construct a necroptosis-related signature (NRS).
  • Evaluated NRS prognostic value across four cohorts and analyzed TME, TMB, and immune infiltration.

Main Results:

  • Identified significant necroptosis heterogeneity, with higher prevalence in epithelial cells, myeloid cells, and fibroblasts.
  • The NRS demonstrated robust prognostic capability, distinguishing high-risk patients across all cohorts.
  • High NRS scores correlated with lower tumor mutation burden (TMB) and reduced immune cell infiltration.
  • TSPAN10 was identified as a key target associated with poor prognosis in cutaneous melanoma.

Conclusions:

  • Necroptosis plays a complex role in cutaneous melanoma progression.
  • The NRS serves as a novel prognostic tool for guiding therapeutic decisions.
  • TSPAN10 represents a promising therapeutic target for cutaneous melanoma treatment.